Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Surfactant Therapy With Budesonide for Prevention of Bronchopulmonary Dysplasia
NCT06855043Phase 2Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2027
- Primary completion
- Aug 2029
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of calfactant, budesonide in bronchopulmonary dysplasia (BPD), respiratory distress syndrome (RDS), sponsored by University of Wisconsin–Madison. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
calfactantbudesonide
03
Conditions
bronchopulmonary dysplasia (BPD)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT06855043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855043.